Combination therapy of itraconazole and an acylhydrazone derivative (D13) for the treatment of sporotrichosis in cats
Isabella Dib Ferreira Gremião,Gabriela Reis Pereira-Oliveira,Sandro Antonio Pereira,Maria Lopes Corrêa,Luana Pereira Borba-Santos,Alessandra Lifsitch Viçosa,Ashna Garg,Krupanandan Haranahalli,Deveney Dasilva,Nivea Pereira de Sa,Gabriel S. Matos,Vanessa Silva,Cristina Lazzarini,Caroline Mota Fernandes,Kildare Miranda,Jhon Jhamilton Artunduaga Bonilla,Anna Letícia Nunes,Leonardo Nimrichter,Iwao Ojima,John Mallamo,John B. McCarthy,Maurizio Del Poeta
DOI: https://doi.org/10.1128/spectrum.03967-23
IF: 3.7
2024-04-22
Microbiology Spectrum
Abstract:ABSTRACT Acylhydrazone (AH) derivatives represent a novel category of anti-fungal medications that exhibit potent activity against Sporothrix sp., both in vitro and in a murine model of sporotrichosis. In this study, we demonstrated the anti-fungal efficacy of the AH derivative D13 [4-bromo- N ′-(3,5-dibromo-2-hydroxybenzylidene)-benzohydrazide] against both planktonic cells and biofilms formed by Sporothrix brasiliensis . In a clinical study, the effect of D13 was then tested in combination with itraconazole (ITC), with or without potassium iodide, in 10 cats with sporotrichosis refractory to the treatment of standard of care with ITC. Improvement or total clinical cure was achieved in five cases after 12 weeks of treatment. Minimal abnormal laboratory findings, e.g., elevation of alanine aminotransferase, were observed in four cats during the combination treatment and returned to normal level within a week after the treatment was ended. Although highly encouraging, a larger and randomized controlled study is required to evaluate the effectiveness and the safety of this new and exciting drug combination using ITC and D13 for the treatment of feline sporotrichosis. IMPORTANCE This paper reports the first veterinary clinical study of an acylhydrazone anti-fungal (D13) combined with itraconazole against a dimorphic fungal infection, sporotrichosis, which is highly endemic in South America in animals and humans. Overall, the results show that the combination treatment was efficacious in ~50% of the infected animals. In addition, D13 was well tolerated during the course of the study. Thus, these results warrant the continuation of the research and development of this new class of anti-fungals.
microbiology